Clinical Trials

Clinical Trials

  Section Menu

CIMAvax Vaccine

Roswell Park has launched the first clinical trial in the U.S. to study the CIMAvax-EGF ® vaccine, a lung cancer treatment. Learn more about CIMAvax.

A clinical trial is a study designed to evaluate a promising new medical treatment. It includes research done to evaluate new ways to prevent and diagnose and/or treat cancer. At Roswell Park, up to 50% of our patients are eligible to enter clinical trials. Many types of treatment can be tested including:

  • New ways of preventing cancer such as drugs, diet, and/or exercise
  • New drugs to treat cancer
  • New ways to use existing treatment such as surgery or radiation therapy

When clinical trials identify new and effective treatments, these treatments will eventually become the new standard of care that will be offered to future patients. Today’s standard treatments were researched and proven by clinical trials done in the past.

Should I participate in a clinical trial? (Learn more about clinical trials from the NCI.)

Recently Opened Clinical Trials

A Registry of Complementary/Alternative Medicine (CAM) Services (Intended for Correlation with Pediatric Cancer and Non-Malignant Hematological Disorders Clinical Symptoms)
Principal Investigator:
Kelly, Kara M
Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Principal Investigator:
Chatta, Gurkamal S
NRG-BR004, "A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer," (NCT03199885)
Principal Investigator:
Levine, Ellis G
A Phase II Neoadjuvant Study of Palbociclib in Combination with Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)
Principal Investigator:
Levine, Ellis G
A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma
Principal Investigator:
Zsiros, Emese
(ALKS 4230-001) A Phase 1 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Principal Investigator:
Ernstoff, Marc S
Palliative Management of Inoperable Malignant Bowel Obstruction: A Prospective, Open Label, Phase-2 Study at an NCI Comprehensive Cancer Center
Principal Investigator:
Case, Amy A
(COG ACNS1721) A Phase 2 Study of Veliparib and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High Grade Glioma (HGG) without H3K27M or BRAFV600E Mutations
Principal Investigator:
Twist, Clare J
(S1801) A Phase II Randomized Study of Adjuvant Versus Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High Risk Melanoma
Principal Investigator:
Ernstoff, Marc S
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma
Principal Investigator:
Chatta, Gurkamal S
Phase 2 Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) with Pembrolizumab, in Subjects Who Have Failed Cisplatin-based Chemotherapy with Locally Advanced (Unresectable) or Metastatic Transitional Cell Cancer (TCC) of the Urothelium
Principal Investigator:
Chatta, Gurkamal S
Phase 2 Study of Nanoliposomal Irinotecan with Fluorouracil and Leucovorin in Refractory Advanced High Grade Neuroendocrine Cancer of GI, Unknown or Pancreatic Origin
Principal Investigator:
Iyer, Renuka V
A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not...
Principal Investigator:
Hillengass, Jens
EA3163:Phase II randomized trial of neo-adjuvant chemotherapy followed by surgery and post-operative radiation versus surgery and post-operative radiation for organ preservation of T3 and T4a nasal and paranasal sinus squamous cell carcinoma (NPNSCC)
Principal Investigator:
Singh, Anurag K
Phase Ib/II Study of Enzalutamide with Venetoclax (ABT-199) in Patients with Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Principal Investigator:
Chatta, Gurkamal S
Phase 1/1b Open-Label, Dose-Escalation Study of APVO436 in Patients with Relapsed or Refractory AML or High-Grade MDS
Principal Investigator:
Wang, Eunice S
Does increased mobility assessed with 3D motion tracking technology lead to early post-operative recovery among patients undergoing genitourinary surgeries
Principal Investigator:
Guru, Khurshid
A Global Randomized Multicenter Phase 3 Trial to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects with High-Risk, Transplant-Eligible Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (TRANSFORM)
Principal Investigator:
Hernandez-Ilizaliturri, Francisco J
A Phase 1 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity
Principal Investigator:
Dy, Grace K
Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients with Metastatic Melanoma
Principal Investigator:
Ernstoff, Marc S
A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
Principal Investigator:
Chatta, Gurkamal S